Zhaojin International: Initiates coverage of Hai Xi New Drug (02637.HK) with a "buy" rating and a target price of HK$280.

According to the Wisdom Finance APP, CMB International issued a research report stating that Haixi Pharmaceuticals (02637.HK) is an innovative commercial pharmaceutical company that integrates research and development, production, and sales. It has 15 approved generic drugs and 4 innovative drugs under research. Among them, HXP056 is expected to become the world's first oral therapy for retinal diseases. It has been given a "buy" rating for the first time, with a target price of HK$280.